Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NOS3 | P29474 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30505637 | 1.00 | CYP2A6 (0.68) | CYP2A6MAOAMAOBTSHRCES1 | |
| SCHEMBL30436320 | 0.97 | CYP2A6 (0.65) | CYP2A6MAOAMAOBTSHRCES1 | |
| SCHEMBL9652088 | 0.97 | CYP2A6 (0.65) | CYP2A6MAOAMAOBTSHRCES1 | |
| SCHEMBL568779 | 0.94 | TSHR (0.71) | CYP2A6MAOAMAOBTSHRCES1 | |
| SCHEMBL31430380 | 0.94 | TSHR (0.71) | CYP2A6MAOAMAOBTSHRCES1 | |
| SCHEMBL30731351 | 0.91 | TSHR (0.67) | CYP2A6MAOAMAOBTSHRCES1 | |
| SCHEMBL30436120 | 0.91 | TSHR (0.67) | CYP2A6MAOAMAOBTSHRCES1 | |
| SCHEMBL31621255 | 0.91 | TSHR (0.67) | CYP2A6MAOAMAOBTSHRCES1 | |
| SCHEMBL31135519 | 0.91 | TSHR (0.67) | CYP2A6MAOAMAOBTSHRCES1 | |
| SCHEMBL30668198 | 0.91 | TSHR (0.67) | CYP2A6MAOAMAOBTSHRCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116925154-A | Dibenzocycloheptyl group-containing pyrido ring metal complex and application thereof in olefin polymerization | 北京服装学院 | 2023-10-24 | — | — | CN | claimed |
| US-20230234907-A1 | METHOD FOR SYNTHESIZING DIBENZOCYCLOHEPTANE DERIVATIVES BY SERIES CYCLIZATION OF FREE RADICALS UNDER ELECTROOXIDATION CONDITIONS | ZHEJIANG NORMAL UNIVERSITY (CN) | 2023-07-27 | — | — | US | claimed |
| CN-116284046-A | Ballon Sha Wei derivative, and preparation method and application thereof | 山东新华制药股份有限公司 | 2023-06-23 | — | — | CN | claimed |
| EP-3544597-A1 | THERAPIES FOR THE TREATMENT OF LIDOCAINE-INEFFECTIVE AND HYPOKALEMIC CONDITIONS | Alkalidx, Inc. (US) | 2019-10-02 | — | — | EP | claimed |
| CN-106631793-B | A kind of preparation method of dibenzocycloheptane derivative | 浙江师范大学 | 2019-03-08 | — | — | CN | claimed |
| CN-108863957-A | Quinoxaline-fused dibenzocycloheptane spiro-ene compound and organic light emitting diode element | 杰秀有限公司 | 2018-11-23 | — | — | CN | claimed |
| WO-2018098273-A1 | THERAPIES FOR THE TREATMENT OF LIDOCAINE-INEFFECTIVE AND HYPOKALEMIC CONDITIONS | ALKALIDX, INC. (US) | 2018-05-31 | — | — | WO | claimed |
| CN-106631793-A | Dibenzo cycloheptane derivative preparation method | 浙江师范大学 | 2017-05-10 | — | — | CN | claimed |
| US-20140350081-A1 | INSECT G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME | US ARMY, SECRETARY OF THE ARMY | 2014-11-27 | — | — | US | claimed |
| WO-2013067519-A2 | INSECT AND TICK G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME | PURDUE RESEARCH FOUNDATION (US) | 2013-05-10 | — | — | WO | claimed |
| US-20030049308-A1 | Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2003-03-13 | — | — | US | claimed |
| EP-1274405-A2 | TRANSDERMAL OR TRANSMUCOSAL DOSAGE FORMS WITH A NICOTINE-CONTAINING ACTIVE SUBSTANCE COMBINATION FOR SMOKER DISINTOXICATION | LTS Lohmann Therapie-Systeme AG (DE) | 2003-01-15 | — | — | EP | claimed |
| WO-2001080837-A2 | TRANSDERMAL OR TRANSMUCOSAL DOSAGE FORMS WITH A NICOTINE-CONTAINING ACTIVE SUBSTANCE COMBINATION FOR SMOKER DISINTOXICATION | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2001-11-01 | — | — | WO | claimed |
| EP-1129704-A1 | Process for targeted administration of active agents on the central nervous system | pharmed Holding GmbH (DE) | 2001-09-05 | — | — | EP | claimed |
| US-5736412-A | COMBINATORIAL APPROACH; OPTIMIZING ABILITY FOR COMPOUNDS TO BIND AT REACTION SITE BY SELECTING COMPOUNDS HAVING GREATEST REACTIVITY | ARQULE, INC. (US) | 1998-04-07 | — | — | US | claimed |
| US-5712171-A | DRUGS WITH PEPTIDE GROUPS FOR BEADS, PLATES MEMBRANES AND COMPOSITES | ARQULE, INC. (US) | 1998-01-27 | — | — | US | claimed |
| US-4505909-A | Method and composition for treating and preventing irritation of the eyes | BERNSTEIN JOEL E (US) | 1985-03-19 | — | — | US | claimed |
| EP-0093373-A1 | Method and composition for treating and preventing irritation of the mucous membranes of the nose | Bernstein, Joel E. (US) | 1983-11-09 | — | — | EP | claimed |
| US-4370324-A | Method and composition for treating and preventing irritation of the eyes | BERNSTEIN JOEL E (US) | 1983-01-25 | — | — | US | claimed |
| EP-0048023-A2 | Composition for treating and preventing irritation of the eyes | Bernstein, Joel E., M.D. (US) | 1982-03-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350081-A1 | INSECT G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME | DDT, ADRA2C, MCHR1 | CYP2A6 994/4885MAOA 342/4885MAOB 370/4885 |
| US-20230234907-A1 | METHOD FOR SYNTHESIZING DIBENZOCYCLOHEPTANE DERIVATIVES BY SERIES CYCLIZATION OF FREE RADICALS UNDER ELECTROOXIDATION CONDITIONS | POR, CYP2E1, CYP2A7 | CYP2A6 41/4885MAOA 1501/4885MAOB 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.